Venous Thromboembolism Prophylaxis in Medically Complex Patients

Venous thromboembolism (VTE) prevention becomes difficult when a hospitalised patient has several competing risks at once. Frailty, cancer, renal impairment, thrombocytopenia, recent surgery, immobility and active bleeding can all change the balance between preventing clot formation and causing harm. The central HM17 lesson was that prophylaxis should be treated as a daily clinical decision rather than a checkbox on an admission order.

Hospitalists must distinguish prophylactic anticoagulation from treatment-dose anticoagulation. A patient with suspected or confirmed deep vein thrombosis (DVT) or pulmonary embolism (PE) needs a diagnostic and therapeutic pathway. A patient who is acutely unwell and largely immobile may need preventive therapy, but the correct option depends on current bleeding risk, kidney function, platelet count and expected mobility.

For Australian clinicians, this approach fits the realities of busy metropolitan services such as Melbourne’s tertiary hospitals and smaller regional facilities where pharmacy, haematology and imaging support may not be immediately available. Local protocols, Therapeutic Guidelines and medicines approved through the Therapeutic Goods Administration (TGA) should support, rather than replace, bedside assessment.

The conference resources from Hospital Medicine 2017 remain useful for revisiting the event’s emphasis on practical hospital medicine, quality improvement and evidence-informed patient care. Applied to VTE prevention, those themes point towards consistent assessment, clear documentation and reliable reassessment during transitions of care.

Start With Individual VTE And Bleeding Risk

Risk scores can prompt a conversation, but they do not replace clinical judgement. A patient’s VTE risk rises with acute infection, heart or respiratory failure, previous VTE, active malignancy, major surgery, prolonged immobility and inflammatory disease. The risk may change quickly after admission, especially when a patient moves from the emergency department to the ward, undergoes a procedure or develops sepsis.

Bleeding risk should be assessed with the same discipline. Look for active bleeding, recent intracranial haemorrhage, recent high-risk surgery, severe uncontrolled hypertension, a falling haemoglobin level, coagulopathy and concurrent antiplatelet or anticoagulant therapy. A stable remote history of gastrointestinal bleeding is not equivalent to ongoing melaena. The decision should record why prophylaxis is being given, withheld or changed.

Choose The Method And Agent Carefully

Low-molecular-weight heparin (LMWH) is commonly preferred for many acutely ill medical patients because it has predictable pharmacokinetics and convenient once-daily administration. Unfractionated heparin (UFH) may be more suitable when renal function is severely reduced, rapid reversal is important or a patient is approaching a procedure. Local formularies and hospital policies determine the exact agent and dose.

Mechanical methods, such as intermittent pneumatic compression, are useful when anticoagulants are temporarily unsafe. They require correct sizing, application and regular checks. They are less effective if left disconnected or removed for long periods, and they may be unsuitable with severe peripheral arterial disease, limb ischaemia, significant oedema or skin injury. Graduated compression stockings should not be treated as a universal substitute for anticoagulant prophylaxis.

Account For Kidney Function, Weight And Age

Renal function can fluctuate rapidly during sepsis, dehydration or contrast exposure. Creatinine-based estimates may be difficult to interpret in a cachectic older person, while a single “normal” creatinine can conceal reduced filtration. When kidney function is unstable, clinicians should consult the local anticoagulation protocol, consider whether UFH offers a safer option and document the monitoring plan.

Extremes of body weight create a different problem. Fixed prophylactic doses may provide inadequate exposure in severe obesity, while frail patients with low body mass may have greater drug exposure than expected. Some hospitals use weight-adjusted strategies or anti-Xa monitoring in selected circumstances, but routine testing is not required for every patient. Age, falls risk and frailty should inform the whole assessment rather than automatically excluding pharmacological prevention.

Manage Thrombocytopenia And Heparin-Induced Thrombocytopenia

A low platelet count needs context. The trend, underlying diagnosis, active bleeding and anticipated trajectory are more informative than an isolated result. Patients with marrow disease, liver disease, sepsis or recent chemotherapy may need a haematology opinion before prophylaxis is started or continued. A falling platelet count after heparin exposure should prompt consideration of heparin-induced thrombocytopenia (HIT), particularly when thrombosis is present or the fall is substantial.

HIT is a prothrombotic emergency, not simply a bleeding problem. Stop all heparin products, including flushes, and use an appropriate alternative under specialist guidance when the clinical probability is significant. Clear medication reconciliation matters because patients may receive heparin from several sources during an admission. In Australian hospitals, a documented allergy or adverse drug reaction and a handover note can prevent inadvertent re-exposure.

Reassess After Procedures And Clinical Changes

Prophylaxis should be paused or modified around neuraxial procedures, lumbar puncture, surgery and invasive bedside interventions according to the relevant timing guidance. The restart decision should consider haemostasis, procedural bleeding risk and the patient’s current VTE risk. “Hold anticoagulation” without a restart time creates avoidable gaps, particularly during overnight handover.

Daily review is especially important in medically complex patients. Ask whether the patient is still bedbound, whether the bleeding risk has changed, whether renal function has worsened and whether a new diagnosis has altered the plan. In Australian wards, where weekend staffing and inter-facility transfers can interrupt continuity, an explicit medication plan in the progress note and discharge summary is a practical safety measure.

Avoid Common Gaps In Hospital Systems

Reliable prophylaxis depends on more than individual prescribing. Admission medication reconciliation should identify pre-existing anticoagulants, antiplatelet medicines and recent VTE treatment. Electronic prescribing systems can support appropriate defaults, but automatic orders may become unsafe when a patient develops bleeding, renal failure or a need for urgent surgery.

A short multidisciplinary review can identify missed doses, inappropriate duplication and mechanical devices that are not being used. Nursing documentation should show whether compression equipment is in place and tolerated. Pharmacists can detect renal dose issues and interactions, while physiotherapists can help define realistic mobility goals. In regional Queensland, Western Australia or remote services, a simple protocol and telehealth access to specialist advice may be particularly valuable when transfer is not immediate.

Practical Checks At The Bedside

• Confirm current mobility, previous VTE, cancer, infection and recent surgery.
• Review haemoglobin, platelet trend, renal function and active bleeding.
• Check every anticoagulant, antiplatelet medicine and heparin exposure.
• Document the reason for the chosen method and the next review point.

Warning Signs Requiring Escalation

• New hypoxia, pleuritic chest pain, syncope or unexplained tachycardia.
• A sudden platelet fall after exposure to heparin.
• Fresh gastrointestinal, urinary, respiratory or intracranial bleeding.
• New unilateral swelling, pain or colour change in a limb.

Translate Prevention Into Discharge Safety

The need for VTE prophylaxis often changes as patients regain mobility, leave acute care or move to rehabilitation. Extended prophylaxis is not appropriate for every medically ill patient, and it should not be continued simply because it appeared on the inpatient medication chart. If it is prescribed beyond discharge, the indication, duration, administration technique and bleeding advice must be clear to the patient and the receiving clinician.

Discharge planning should account for Australia’s varied care pathways. A patient returning to a rural town may rely on a general practice clinic or community pharmacy for follow-up, while someone transferred between a public hospital and private rehabilitation facility may encounter different electronic records and formularies. A plain-language medication list, documented stop date and communication with the GP reduce the risk of accidental continuation or omission.

Put The HM17 Lessons Into Daily Practice

The most useful takeaway is a repeatable process: assess VTE risk, assess bleeding risk, choose the least hazardous effective method, check patient-specific factors, and review the decision whenever the clinical situation changes. This process accommodates complex cases without pretending that every patient fits a score or standard order set.

For hospitalists, the quality measure is not simply the percentage of eligible patients who receive an anticoagulant. Safer care also asks whether contraindications were recognised, whether mechanical prophylaxis was used correctly, whether missed doses were addressed and whether the plan survived handover. In practice, a documented daily decision is often more valuable than an unexamined standing order.

The practical takeaway is straightforward: for every medically complex inpatient, make VTE and bleeding risk visible in the record, select prophylaxis that matches the current physiology, and set a definite time to review or stop it.